Richard A. Miller - Mar 31, 2023 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
President and CEO, Director
Signature
/s/ Leiv Lea, as Attorney-in-Fact for Richard A. Miller
Stock symbol
CRVS
Transactions as of
Mar 31, 2023
Transactions value $
$0
Form type
4
Date filed
4/3/2023, 04:30 PM
Previous filing
Dec 16, 2022
Next filing
Jun 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +800K $0.00 800K Mar 31, 2023 Common Stock 800K $0.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from March 31, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.